开云app官网登录入口网页版-官方正版

#Durvalumab#

3篇内容 | 1731人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2092790, encodeId=6e7e2092e9092, content=<a href='/topic/show?id=a9ba633888' target=_blank style='color:#2F92EE;'>#Durvalumab#</a>联合EP成为广泛期SCLC<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>, objectTitle=Durvalumab联合EP成为广泛期SCLC小细胞肺癌一线治疗新选择, objectType=article, longId=180960, objectId=63fa180960d4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201910/20191011131042209.jpg, objectUrl=/article/show_article.do?id=63fa180960d4, replyNumber=0, likeNumber=103, createdTime=2022-10-10, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63fa180960d4, moduleTitle=Durvalumab联合EP成为广泛期SCLC小细胞肺癌一线治疗新选择, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=63fa180960d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1052879, encodeId=3aa110528e9b9, content=<a href='/topic/show?id=a9ba633888' target=_blank style='color:#2F92EE;'>#Durvalumab#</a>研究表明，PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗具有改善无复发生存期的临床获益，并且跟PD-L1水平有一定相关。, objectTitle=Durvalumab, objectType=topic, longId=6338, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=127, createdTime=2021-09-18, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=919023, encodeId=d87191902315, content=<a href='/topic/show?id=a22d1e57696' target=_blank style='color:#2F92EE;'>#TNBC#</a>患者<a href='/topic/show?id=4012e904074' target=_blank style='color:#2F92EE;'>#维持治疗#</a>中<a href='/topic/show?id=a9ba633888' target=_blank style='color:#2F92EE;'>#Durvalumab#</a>的单药，在激素受体阳性和Her2阴性的患者中，维持化疗比durvalumab更有效。这需要进一步研究！, objectTitle=Nat Med：转移性乳腺癌中Durvalumab与维持化疗的疗效比较, objectType=article, longId=206034, objectId=c40a2060347b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021121/1611240656694_2467676.PNG, objectUrl=/article/show_article.do?id=c40a2060347b, replyNumber=0, likeNumber=253, createdTime=2021-01-22, rootId=0, userName=lifefamily, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c40a2060347b, moduleTitle=Nat Med：转移性乳腺癌中Durvalumab与维持化疗的疗效比较, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c40a2060347b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

Durvalumab

2020-05-29

lifestar (审核中...)

前往app查看评论内容

#Durvalumab#联合EP成为广泛期SCLC#小细胞肺癌#

Durvalumab联合EP成为广泛期SCLC小细胞肺癌一线治疗新选择

2022-10-10

yangchou (审核中...)

前往app查看评论内容

#Durvalumab#研究表明，PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗具有改善无复发生存期的临床获益，并且跟PD-L1水平有一定相关。

2021-09-18

lifefamily (审核中...)

前往app查看评论内容

#TNBC#患者#维持治疗#中#Durvalumab#的单药，在激素受体阳性和Her2阴性的患者中，维持化疗比durvalumab更有效。这需要进一步研究！

Nat Med：转移性乳腺癌中Durvalumab与维持化疗的疗效比较

2021-01-22

科室
- - 订阅+
  - 更多科室
工具
服务